패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alkermes plc는 36명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
null null	Baird
Joel Beatty	Baird
Luke Herrmann	Baird

Alkermes 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Alkermes plc (NasdaqGS:ALKS) announces an Equity Buyback for $400 million worth of its shares.

Recent updates

Alkermes plc Announces Positive Topline Results from Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients with Narcolepsy Type 2

Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 11%

New major risk - Revenue and earnings growth

Alkermes plc (NasdaqGS:ALKS) entered into a definitive agreement to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $1.8 billion.

Alkermes plc to Report Q3, 2025 Results on Oct 28, 2025

Investor sentiment improves as stock rises 15%

Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025

Alkermes: A More Than Solid Quarter

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Alkermes plc to Report Q2, 2025 Results on Jul 29, 2025

Insufficient new directors

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation?

Alkermes plc to Present New Research Related to Alks 2680 At Sleep 2025

First quarter 2025 earnings: EPS exceeds analyst expectations

Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors

Alkermes plc Announces Demise of Iain M. Brown, Chief Financial Officer

Investor sentiment deteriorates as stock falls 16%

Alkermes plc, Annual General Meeting, May 21, 2025

Price target increased by 9.5% to US$37.64

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Insider notifies of intention to sell stock

Alkermes plc Provides Earnings Guidance for 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alkermes plc to Report Q4, 2024 Results on Feb 12, 2025

Insider notifies of intention to sell stock

Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price

We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Insider notifies of intention to sell stock

Third quarter 2024 earnings: EPS misses analyst expectations

Alkermes plc to Report Q3, 2024 Results on Oct 24, 2024

Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

New major risk - Revenue and earnings growth

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Alkermes: Fairly Valued After Post-Earnings Bump

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Alkermes plc to Report Q1, 2024 Results on May 01, 2024

Alkermes plc, Annual General Meeting, May 31, 2024

Price target increased by 7.3% to US$35.50

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

New minor risk - Shareholder dilution

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Consensus EPS estimates increase by 52%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

Alkermes plc (NasdaqGS:ALKS) announces an Equity Buyback for $400 million worth of its shares.

Alkermes plc to Report Q4, 2023 Results on Feb 15, 2024

Alkermes plc Announces Executive Changes

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Alkermes plc Announces Changes to its Board

Alkermes plc Revises Earnings Guidance for the Fiscal Year 2023

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Price target decreased by 7.5% to US$33.10

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkermes plc to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc to Report Q2, 2023 Results on Jul 26, 2023

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Forecast breakeven date moved forward to 2023

Sarissa Issues Presentation for Alkermes Shareholders